About PGDx

Management Team

Samuel Angiuoli
Samuel Angiuoli, PhD
Chief Information Officer
Dr. Samuel Angiuoli is a computer scientist with over a decade of experience in bioinformatics and a deep understanding of the information technology challenges associated with genomics. Prior to joining PGDx, Dr. Angiuoli directed bioinformatics teams at leading genome sequencing facilities, including The Institute for Genomic Research, J. Craig Venter Institute, and the Institute for Genome Sciences at the University of Maryland, School of Medicine. Dr. Angiuoli received a PhD in computer science from the University of Maryland and a B.S. with distinction from Duke University majoring in both chemistry and computer science.
Cindy Caccuro
Cindy Caccuro
Vice President, Molecular Lab Sales
Ms. Cindy Caccuro is an experienced sales executive with a 16-year track record of achieving outstanding results in individual and team sales in the life sciences industry. Cindy has helped over 75 accounts create CLIA approved physician labs leading to increased revenues and a more personalized approach in pathology. She joined PGDx from Miraca Life Sciences where she was the Regional Vice President, managing a sales team with a focus in anatomical pathology. Cindy earned a B.A. in Economics with a minor in Biology from Rutgers University.
Maria Chan
Maria Chan, PhD
Vice President, Regulatory Strategy

Dr. Maria Chan, has joined the PGDx as Vice President of Regulatory Strategy. Dr. Chan will play a major role in shaping regulatory strategy at PGDx and will oversee all regulatory activities. Previously, Dr. Chan was the FDA Division Director, Division of Immunology & Hematology Devices at the Center for Devices & Radiological Health, Office of In Vitro Diagnostics & Radiological Health, where she headed four branches including Immunology, Hematology, Pathology and Genetics. Earlier in her career at the FDA, Dr. Chan was promoted from Scientific to Team Leader and then Associate Division Director for the Immunology Branch. Prior to the FDA, Dr, Chan was Director of Immunology and Director of Technical Services in the Department of Laboratory Medicine at the Children’s National Health System. During this period she was also Associate Professor, Departments of Pediatrics and Pathology at the George Washington University Medical Center. Early in her career, Dr. Chan was Associate Director of the Immunogenetics Laboratory and an Assistant Professor in the Division of Medical Genetics at the Johns Hopkins University School of Medicine. Dr. Chan received a BA degree from the University of Oregon and a PhD in Immunology from the State University of New York at Buffalo. She completed post-doctoral training in Immunogenetics at Johns Hopkins.

Luis Diaz
Luis Diaz, MD
Dr. Luis Diaz is a leading authority in oncology, having developed personalized diagnostic and therapeutic approaches for cancer. Dr. Diaz is a pioneer in circulating tumor DNA analyses in human cancer, having performed landmark studies in the field. Dr. Diaz is Head of the Division of Solid Tumor Oncology in Memorial Sloan Kettering’s Department of Medicine. He is also a medical oncologist who cares for people with advanced colon cancer and pancreatic cancer and a researcher applying cancer genetics to find new ways to diagnose and treat the disease.  Dr. Diaz has undergraduate and medical degrees from the University of Michigan, and completed post-doctoral training at Johns Hopkins University.
Jennifer Dickey, PhD, RAC
Jennifer Dickey, PhD, RAC
Director, Regulatory & Quality

Dr. Jennifer Dickey has joined PGDx as Director of Regulatory and Quality.  Dr. Dickey comes with an impressive background having most recently been with the FDA as Senior Scientific Reviewer in the Molecular Genetics branch of the Office of In Vitro Diagnostics and Radiological Health. Dr. Dickey has more than 7 years of regulatory review experience and was Regulatory Affairs Certified (RAC) through the Regulatory Affairs Professional Society (RAPS) in 2012. Dr. Dickey has played a leadership role in several regulatory initiatives including serving as Chair of the Next Generation Sequencing-based Oncology Panels Public Workshop (February 25, 2016) and as lead reviewer for the first NGS-based assay (Illumina assay for cystic fibrosis).  Dr. Dickey has spoken at several association conferences on subjects such as Regulatory Review of NGS Assays; Potential Roles for NGS in Companion Diagnostics; FDA Review of NGS Technologies; Multi-Analyte NGS Assays; and Enabling NGS in Global Clinical Trials, additionally Dr. Dickey has co-authored numerous peer-reviewed articles.

Melody Gretz
Melody Gretz
Vice President, Marketing & Market Access
Ms. Melody Gretz has worked in a variety of commercial and business development roles in the diagnostic and payer markets for 15+ years with a passion for enabling wide-spread, affordable access to high quality, clinically relevant diagnostic tools. She joined PGDx from Quest Diagnostics where she held a variety of roles including business development, marketing, and health plans. Most recently she led the acquisition and integration of Solstas Lab Partners. Melody earned a B.A. in Economics, Politics and French from Washington & Lee University as well as an M.B.A from Columbia Business School.
Siân Jones
Siân Jones, PhD
Vice President, Genome Sciences
Dr. Sian Jones was a member of the Johns Hopkins University team that sequenced a cancer genome for the first time, and has since used this approach at PGDx to identify genes with critical roles in a range of tumor types. She leads the team that analyzes sequence data where the goal is to provide meaningful information to aid in interpreting results of these complex analyses. Previously, she was a Post-doctoral Fellow at the Ludwig Center for Cancer Genetics and Therapeutics. Dr. Jones earned a Ph.D. in Cancer Genetics from Cardiff University.
Maura Kadan
Maura Kadan, RN, MSN, OCN
Director, Clinical Operations
Ms. Maura Kadan has over 10 years of experience in oncology nursing before joining PGDx. She served as a staff nurse on the Heme-oncology in-patient unit and the Clinical Program Manager for GI Malignancies at Johns Hopkins Hospital. Maura’s unique experience and skill set enables PGDx to connect patients and health care teams with resources needed to make informed choices. Maura earned B.S in Health and Physical Education from Roanoke College, and a B.S.N & M.S.N from John Hopkins University School of Nursing.
Lisa Kann
Lisa Kann, PhD
Vice President, Lab Operations
Dr. Lisa Kann has worked in Molecular Genetics for the past 16 year with an impressive background collaborating at the Whitehead Institute, Exact Sciences and Genzyme Genetics. Lisa was the first employee of PGDx in 2011 and helped usher in the Company’s first CLIA assays. Dr. Kann received a B.A. in Biology from Oberlin College as well as a PhD from the University of Rhode Island.
James Lewis
James Lewis
Senior Vice President, Corporate Development

Mr. James Lewis joined Personal Genome Diagnostics as Senior Vice President, Corporate Development in November 2016 from Esperance Pharmaceuticals, where he served as Vice President, Business Development and a member of the management team.  Jim is a life science industry executive with more than 25 years of growth-oriented corporate leadership experience across a spectrum of strategic planning, general management, business development, fundraising and commercial roles at companies including AstraZeneca, plc., Biosyn, Inc., ViroPharma, Inc. and TAP Pharmaceuticals.  Jim has also recently served as a business advisor and consultant for emerging stage life science companies including Jenrin Discovery, Zelos Therapeutics, Amorcyte, Inc. and Azur Pharma.

Abigail McElhinny
Abigail McElhinny
Senior Vice President, Research & Development and Operations
Dr. Abigail McElhinny joined Personal Genome Diagnostics as Senior Vice President, Research & Development and Operations in May 2016 from Ventana Medical Systems (Roche Tissue Diagnostics), where she held a number of different roles of increasing responsibilities. At Ventana, Abigail held the position as Vice President of Assay and Reagent Development where she built and led Research & Development teams with the goal of developing new assays for the BenchMark and next generation platforms. Dr. McElhinny represented Ventana on the pivotal PD-L1 Blueprint initiative, and successfully oversaw key scientific projects critical to the business, while her organization doubled in size. Abigail previously served as Senior Project Leader for CDx lifecycle projects, working with regulatory, clinical affairs, quality, and biostatistics teams to build the necessary processes and requirements to support pharma clinical trials and obtain FDA approval for CDx assays, including Ventana’s ALK (D5F3) CDx IHC assay and HER2 Dual ISH assays. Abigail received her Ph.D from Northeastern University in Immunology and Biochemistry, and completed a post-doctoral fellowship at University of Arizona in Cell Biology, focused on molecular mechanisms of cardiac muscle development, cardiomyopathies and muscle remodeling.
Antony Newton
Antony Newton
Senior Vice President, Pharma Partnering
Mr. Antony Newton joined Personal Genome Diagnostics as Senior Vice President, Pharma Partnering in 2012 and has 30 years’ experience leading the commercialization of complex life sciences technologies at Amersham International (GE Life Sciences), Sigma-Aldrich, Enzymatix, and Genzyme Corporation. Most recently Mr. Newton was a Vice President in Genzyme’s oncology business as part of the team that built the business from conception through to therapeutic marketing. In this role he led the program and portfolio management process as well as alliance and collaboration management functions. Mr. Newton has a M.Sc. from Brunel University, London and a PG Dip (DMS) from Anglia Ruskin University, Cambridge.
Mark Sausen
Mark Sausen, PhD
Vice President, Research & Development
Dr. Mark Sausen joined Personal Genome Diagnostics in 2013 and currently serves as the Vice President of Research and Development. His prior research has focused on the development of novel tissue and cell free DNA-based genomic approaches for the detection and analysis of cancer. Dr. Sausen has authored and co-authored several peer-reviewed articles in journals such as Science, Nature Genetics, and Science Translational Medicine on these topics. He received his B.A. from the University of Delaware in Biological Sciences and PhD from Johns Hopkins University in Cellular and Molecular Medicine where he received the Hans J. Prochaska Young Investigator’s Award.
William Stevens
William Stevens
Chief Financial Officer
Mr. William Stevens has over 20 years of financial, operational and general management experience. Prior to joining the PGDx in 2010, William was the corporate controller, officer and Vice-President of Custom Direct, a publically traded marketing company with sales in excess of $100 million that was acquired by Deluxe Corporation where led a team of over 300 people. He previously worked as a management consultant for RSM McGladrey and Clifton Larson where he provided valuation, litigation support, troubled company, lean manufacturing, and process reengineering consulting services. William received his B.B.A in Finance and a M.B.A in Accounting from Loyola University.
Victor Velculescu
Victor Velculescu, MD, PhD
Dr. Victor Velculescu is internationally known for his discoveries in genomics and cancer research. He and his colleagues have pioneered a variety of genomic technologies and were the first to perform genome-wide sequence analyses in human cancer. These analyses identified a variety of genes not previously known to be involved in neoplasia, including PIK3CA as one of the most highly mutated genes in human tumors. He is Professor of Oncology and Co-Director of Cancer Biology at Johns Hopkins Kimmel Cancer Center. Dr. Velculescu has a B.S. from Stanford University, and MD, PhD degrees and postdoctoral training from Johns Hopkins University.
Douglas Ward
Douglas Ward
Chief Executive Officer
Mr. Doug Ward joined Personal Genome Diagnostics as Chief Executive Officer and a member of the board of directors in May 2016 from Roche, where he served as Vice President Companion Diagnostics (CDx) for Ventana Medical System. He has more than 25 years of experience within the diagnostic market and most recently has been responsible for creating Ventana’s CDx strategy, establishing Ventana’s innovative pharma partnering co-development business model, and achieving the market leading position in tissue based companion diagnostics. Prior to joining Roche, Mr. Ward served as President of the America’s Commercial Operations for GE Healthcare Life Sciences Business. Previously, he was Country Head of the UK and Ireland for Siemens Healthcare Diagnostics and Vice President of Marketing and Scientific Affairs for Bayer Diagnostics’ Molecular Diagnostics business unit. In addition, he has held leadership positions with Chiron Diagnostics and Ciba Corning Diagnostics. Doug received his BA from Ohio Wesleyan University in Pre-Medicine and Pre-Professional Zoology.